Related Experiment Videos
Dose-response relationship with venlafaxine
1Department of Psychiatry and Behavioral Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA.
Journal of Clinical Psychopharmacology
|June 1, 1996
Summary
Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, effectively treated major depression in outpatients. Studies showed a dose-response relationship, indicating greater efficacy with higher dosages and flexible dosing schedules.
Area of Science:
- Psychiatry and Clinical Pharmacology
- Neuroscience and Behavioral Science
Background:
- Selecting first-line antidepressants involves considering dose-response flexibility.
- Venlafaxine is a novel serotonin and norepinephrine reuptake inhibitor (SNRI).
Purpose of the Study:
- To evaluate the efficacy and dose-response relationship of venlafaxine in treating major depression.
- To assess the safety and tolerability of venlafaxine in outpatient settings.
Main Methods:
- Two randomized, placebo-controlled studies were conducted.
- Participants were outpatients diagnosed with major depression.
- Efficacy was measured using the Hamilton Rating Scale for Depression (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impressions (CGI) scale.
Main Results:
- Venlafaxine demonstrated significant efficacy compared to placebo across all measured scales.
- Evidence of a positive dose-response relationship was observed in both studies.
- Venlafaxine was found to be safe and well-tolerated at tested dosages (administered twice or three times daily).
Conclusions:
- Venlafaxine is an efficacious, safe, and tolerable first-line treatment option for major depression in outpatients.
- The drug exhibits a dose-response relationship, offering flexibility in optimizing treatment.
- Further research may explore optimal dosing strategies for diverse patient populations.